Intersect ENT’s Resolve sinus implant meets endpoints in pivotal trial

Intersect ENT (NSDQ:XENT) said today that its Resolve sinus implant met both primary endpoints in its Resolve II pivotal trial.

The Menlo Park, Calif.-based company’s Resolve steroid-releasing sinus implant is a minimally invasive treatment for patients with recurrent ethmoid sinus obstruction. The 300-patient Resolve II trial compared the bilateral Resolve implant with a sham procedure.

Get the full story at our sister site, Drug Delivery Business News.

The post Intersect ENT’s Resolve sinus implant meets endpoints in pivotal trial appeared first on MassDevice.

from MassDevice http://ift.tt/2eb4Vxm